Реферати » Реферати з біології » Механізми стійкості пухлин до цисплатину

Механізми стійкості пухлин до цисплатину

repair-mediated resistance to cis-diamminedichloroplatinum (II). Cancer Res 1998, 58 (6): 1120-3.

69. Mestdach N, Pommery N, Saucier JM, Hecquet B, Founier C,

Slomianny C, Teissier E, Henichart JP. Chemoresistance to doxorubicin and cisplatin in a murine cell line. Analysis of P-Glycoprotein, topoisomerase II activity, glutathione and related enzymes.

Anticancer Res 1994; 14: 869-74.

70. Kondo H, Kanzawa F, Nishio K, Saito S, Saijo N. In vitro and in vivo effects of cisplatin and etoposide in combination on small cell lung cancer cell lines. Jpn J Cancer Res 1994; 85: 1050-6.

71. Jong S, Timmer-Bosscha H, Vries EGE, Mulder NH. Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line. Int J Cancer 1993; 53: 110-7.

72. Guchelaar HJ, Timmer-Bosscha H, Dam-Meiring A, Uges DRA,

Oosterhuis JW, Vries EGE Mulder NH. Enhancement of cisplatin and etoposide cytotoxicity after all-trans retinoic-acid-induced cellular differentiation of a murine embryonal carcinoma cell line. Int J

Cancer 1993; 55: 442-7.

73. Seki S, Hongo A, Zhang B, Akiyama K, Sarker AH, Kudo T.

Inhibition of cisplatin-mediated DNA damage in vitro by ribonucleotides. Jpn J Cancer Res 1993; 84: 462-7.

74. Parekh HK, Simpkins H. The differential expression of citokeratin 18 in cisplatin-sensitive and-resistant human ovarian adenocarcinoma cells and its association with drug sensitivity.

Cancer Res 1995; 55: 5203-6.

75. Mirakhur B, Parekh HK, Simpkins H. Expression of the cisplatin resistance phenotype in a human ovarian carcinoma cell line segregates with chromosomes 11 and 16. Cancer Res 1996; 56: 2256-

62.

76. Mueller H, Eppeberger U. The dual role of mutant p 53 protein in chemosensitivity of human cancers. Anticancer Res 1996, 16 (6B): 3845-

8.

77. Kawasaki t, Tomita Y, Bilim V, Takeda M, Takahashi K, Kumanishi

T. Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p 21/WAF1/CIP1 and / or p 53 gene alterations. Int J Cancer 1996, 68 (4): 501-5.

78. Kondo S, Barna BP, Kondo Y, Tanaka Y, Casey G, Liu J, Morimura T,

Kaakaji R, Peterson JW, Werbel B, Barnett GH. WAF1/CIP1 increases the susceptibility of p 53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene 1996, 13 (6): 1279-85.

79. Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced apoptosis in melanoma cells is p 53 dependent. Melanoma Res 1998, 8

(1): 17-23.

80. Biagosklonny MV, El-Deiry WS. Acute overexpression of wt p 53 facilitates anticancer drug-induced death of cancer and normal cells.

Int J Cancer 1998, 75 (6): 933-940.

81. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R,

Goldginger N, Pei H, Prokocimer M, Rotter V. Mutant p 53 protein interferes with p 53-independent apoptotic pathways. Oncogene 1998,

16 (25): 3269-77.

82. Vasey PA, Jones NA, Jenkins S, Dive C, Broun R. Cisplatin, camptothecin, and taxol sensitivities of cells with p 53-associated multidrug resistance. Mol Pharmacol 1996, 50 (6): 1536-40.

83. Vikhanskaya F, Clerico L, Valenti M, Stazione NS, Broggini M,

Parodi S, Russo P. Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p 53. Int J Cancer 1997, 72 (1): 155-9.

84. Vaisman A, Varchenko M, Said I, Chaney SG. Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 1997,

27 (1): 54-64.

85. Siddik ZH, Mims B, Lozano G, Thai G. Independent pathways of p 53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 1998, 58 (4): 698-703.

86. Ju JF, Banerjee D, Lenz HJ, Danenberg KD, Schmittgen TC, Spreas

CP, Schonthal AH, Manno DJ, Hochhauser D, Bertino JR, Danenberg PV.

Restoration of wild-type p 53 activity in p 53-null HL-60 cells confers multidrug sensitivity. Clin Cancer Res 1998, 4 (5): 1315-22.

87. Fajac A, Da Silva J, Ahomadegbe JC, Rateau JG, Bernaudin JF, Riou

G, Benard J. Cisplatin-induced apoptosis and p 53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer

1996, 86 (1): 67-74.

88. Kondo S, Barna BP, Morimura T, Takeuchi J, Yuan J, Akbasak A,

Barnett GH. Interleukin-1-beta-converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells. Cancer Res 1995, 55

(24): 6166-71.

89. De Feudis P, Debernardis D, Beccaglia P, Valenti M, Sire GE,

Arzani D, Stanzione S, Parodi S, D `Incalci M, Russo P, Broggini M.

DDP-induced cytotoxicity is not influenced by p 53 in nine human ovarian cancer cell lines with different p 53 status. Br J Cancer

1997, 76 (4): 474-9.

90. Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G. Expression of p 53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumor cell lines. Br J Cancer 1998, 77 (10): 1562-7.

91. Ikeguchi M, Tatebe S, Kaibara N, Ito H. Changes in levels of expression of p 53 and the product of the bcl-2 in lines of gastric cancer cells during cisplatin-induced apoptosis . Eur Surg Res 1997,

29 (5), 396-402.

92. Pestell KE, Medlow CJ, Titley JC, Kelland LR, Walton MI.

Characterisation of the p 53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer 1998, 77 (6): 913-8.

93. Nakata B, Chung KH, Ogawa M, Yanagawa K, Muguruma K, Inoue T,

Yamashita Y, Onoda N, Maeda K, Sawada T, Sowa. P 53 protein overexpression as a predictor of the response to themotherapy in gastric cancer. Surg Today 1998, 28 (6): 595-8.

94. Petty R, Evans A, Duncan I, Kurbacher C, Cree I. Drug resistance in ovarian cancer - the role of p 53. Payhol Oncol Res 1998, 4 (2):

97-102.

95. Simonian PL, Grillot DA, Andrews DW, Leber B, Nunez G. Bax homodimerization is not required for Bax to accelarate chemotherapy-induced cell death. J Biol Chem 1996, 271 (50): 32073-7.

96. Liu JR, Fletcher B, Page C, Hu C, Nunez G Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol 1998, 70 (3), 398-403.

97. Miyake H. Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, Eto

H, Gohji K, Arakawa S, Kamidono S, Saya H. Overexpression of Bcl-2 in bladder cancer inhibits apoptosis induced by cisplatin and adenoviral-mediated p 53 gebe transfer. Oncogene 1998, 16 (7): 1933-43.

98. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-xl can confer a multidrug resistance phenotype. Blood 1995, 86 (5): 1903-

10.

99.Simonian PL, Grillot AM, Nunez G. Bcl-2 and Bcl-Xl can differentially block chemotherapy induced cell death. Blood 1997, 90

(3): 1208-16.

100. Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C. Cisplatin-and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p 53. Mol Pharmacol 1998, 53 (3): 819-26.

101. Boersma AW, Nooter K, Burger h, Kortland CJ, Stoter G. Bax upregulation is an early event in cisplatin-induced apoptosis in human testicular germ-cell tumor cell line NT2, as quantitated by flow cytometry. Cytometry 1997, 27 (3): 275-82.

102. Lee JU, Hosotani R, Wada H, Doi R, Kosiba T, Fujimoto K,

Miyamoto Y, Mori C, Nakamura N, Shiota K, Imamura M. Mechanism of apoptosis induced by cisplatin and VP-16 in PANC-1

Сторінки: 1 2 3 4 5 6 7